ARA290 (Research-Grade Peptide)

Erythropoietin-derived peptide (innate repair receptor agonist) — for laboratory research only

Product Overview

ARA290, also known as cibinetide, is a synthetic peptide derived from the tertiary structure of erythropoietin (EPO).
Unlike full-length EPO, ARA290 does not stimulate erythropoiesis and instead selectively activates the innate repair
receptor (IRR), a heteromeric receptor complex involved in tissue protection and inflammatory modulation. ARA290 has
been investigated in preclinical and clinical research models related to neuropathy, inflammation, and tissue injury.
Supplied as a high-purity lyophilized powder, this material is intended strictly for laboratory research use and is not
approved for human or veterinary administration.

Research Highlights

• Innate Repair Receptor Activation: ARA290 selectively binds the innate repair receptor without activating
  the classical erythropoietin receptor, avoiding erythropoietic effects.
  PNAS
• Neuropathic Pain Models: Research has shown ARA290 reduces neuropathic pain behaviors and supports nerve
  fiber repair in diabetic and small-fiber neuropathy models.
  Diabetes
• Anti-Inflammatory Signaling: Studies indicate ARA290 modulates inflammatory cytokine pathways and reduces
  tissue inflammation without immunosuppression.
  Journal of Neuroinflammation
• Tissue Protection Research: ARA290 has been investigated in models of ischemic injury, sarcoidosis, and
  autoimmune-associated tissue damage, highlighting its cytoprotective properties.
  Molecular Medicine

Product Details & Handling

• Synonyms: ARA290; Cibinetide
• Form: Lyophilized powder, supplied in sterile vials
• Purity: ≥ 98% (Certificate of Analysis provided)
• Quantity: 30 MG per vial
• Storage: Store at –20 °C; protect from light and moisture
• Handling: For use only in controlled laboratory environments with appropriate PPE; consult SDS for safety information

Legal Disclaimer

This product is provided strictly for laboratory research use only.
It is not intended for human or veterinary consumption, therapeutic, diagnostic, or clinical application.
Customers are responsible for compliance with all applicable laws and institutional policies.
ARA290 is an investigational research compound and is not approved by the FDA as a drug, supplement, or treatment.
Windy City Peptide does not provide medical advice or support related to human use.